Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
CIPRO XR is an extended-release oral tablet formulation of ciprofloxacin, a fluoroquinolone antibiotic developed by Bayer. The mechanism of action involves inhibition of bacterial DNA gyrase and topoisomerase IV, making it effective against a broad spectrum of gram-negative and gram-positive bacteria. Indications and specific clinical uses are not documented in the provided data.
LOE-approaching status suggests downsizing or transition planning within the brand team; commercial roles may face consolidation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections
A Phase IV Study of Cipro XR in Uncomplicated UTI
Working on CIPRO XR offers limited growth opportunity due to LOE-approaching status; roles focus on defending market share, managing generic transition, and compliance. Career mobility may be constrained as the brand enters decline phase.
Worked on CIPRO XR at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.